Literature DB >> 32238434

Qualitative Variation among Commercial Immunoassays for Detection of Measles-Specific IgG.

Donald R Latner1, Sun B Sowers1, Kiana Anthony1, Heather Colley2, Christine Badeau2, Jessica Coates3, Phili Wong1, Yetunde Fakile4, Cristina Interiano5, Kevin B Pannell5, Van Leung-Pineda5,6, Manisha M Patel1, Paul A Rota1, Brandi M Limbago1, Carole J Hickman7.   

Abstract

Measurement of measles virus-specific IgG is used to assess presumptive evidence of immunity among immunocompetent individuals with uncertain immune or vaccination status. False-negative test results may lead to unnecessary quarantine and exclusion from activities such as employment, education, and travel or result in unnecessary revaccination. In contrast, false-positive results may fail to identify susceptible individuals and promote spread of disease by those who are exposed and unprotected. To better understand the performance characteristics of tests to detect measles IgG, we compared five widely used, commercially available measles IgG test platforms using a set of 223 well-characterized serum samples. Measles virus neutralizing antibodies were also measured by in vitro plaque reduction neutralization, the gold standard method, and compared to IgG test results. Discrepant results were observed for samples in the low-positive ranges of the most sensitive tests, but there was good agreement across platforms for IgG-negative sera and for samples with intermediate to high levels of IgG. False-negative test results occurred in approximately 11% of sera, which had low levels of neutralizing antibody.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  ELISA; IgG; immunity testing; measles; neutralizing antibody; plaque reduction neutralization

Mesh:

Substances:

Year:  2020        PMID: 32238434      PMCID: PMC7269388          DOI: 10.1128/JCM.00265-20

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Vaccine-modified measles in previously immunized children in Accra, Ghana: clinical, virological and serological parameters.

Authors:  N Ishiwada; M M Addae; J K Tetteh; S M Yempewu; D Ofori-Adjei; H Kamiya; B D Akanmori
Journal:  Trop Med Int Health       Date:  2001-09       Impact factor: 2.622

Review 2.  Summary and conclusions: measles elimination meeting, 16-17 March 2000.

Authors:  Samuel L Katz; Alan R Hinman
Journal:  J Infect Dis       Date:  2004-05-01       Impact factor: 5.226

3.  Measles elimination in the United States.

Authors:  Walter A Orenstein; Mark J Papania; Melinda E Wharton
Journal:  J Infect Dis       Date:  2004-05-01       Impact factor: 5.226

4.  Mild measles and secondary vaccine failure during a sustained outbreak in a highly vaccinated population.

Authors:  M B Edmonson; D G Addiss; J T McPherson; J L Berg; S R Circo; J P Davis
Journal:  JAMA       Date:  1990-05-09       Impact factor: 56.272

5.  Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination.

Authors:  Bernard J Cohen; Susette Audet; Nick Andrews; Judy Beeler
Journal:  Vaccine       Date:  2007-11-12       Impact factor: 3.641

Review 6.  Strategies for minimizing nosocomial measles transmission.

Authors:  R J Biellik; C J Clements
Journal:  Bull World Health Organ       Date:  1997       Impact factor: 9.408

7.  Two case studies of modified measles in vaccinated physicians exposed to primary measles cases: high risk of infection but low risk of transmission.

Authors:  Jennifer S Rota; Carole J Hickman; Sun Bae Sowers; Paul A Rota; Sara Mercader; William J Bellini
Journal:  J Infect Dis       Date:  2011-07       Impact factor: 5.226

8.  Emergence of Attenuated Measles Illness Among IgG-positive/IgM-negative Measles Cases: Victoria, Australia, 2008-2017.

Authors:  Katherine B Gibney; Lucy O Attwood; Suellen Nicholson; Thomas Tran; Julian Druce; Julia Healy; Janet Strachan; Lucinda Franklin; Robert Hall; Gail B Cross
Journal:  Clin Infect Dis       Date:  2020-03-03       Impact factor: 9.079

9.  Global measles elimination efforts: the significance of measles elimination in the United States.

Authors:  Peter M Strebel; Ana-Maria Henao-Restrepo; Edward Hoekstra; Jean-Marc Olive; Mark J Papania; Stephen L Cochi
Journal:  J Infect Dis       Date:  2004-05-01       Impact factor: 5.226

10.  Assessment of the Status of Measles Elimination in the United States, 2001-2014.

Authors:  Paul A Gastañaduy; Prabasaj Paul; Amy Parker Fiebelkorn; Susan B Redd; Ben A Lopman; Manoj Gambhir; Gregory S Wallace
Journal:  Am J Epidemiol       Date:  2017-04-01       Impact factor: 4.897

View more
  2 in total

1.  Preservation of lymphocyte functional fitness in perinatally-infected and treated HIV+ pediatric patients displaying sub-optimal viral control.

Authors:  Aaruni Khanolkar; William J Muller; Bridget M Simpson; Jillian Cerullo; Ruth Williams; Sun Bae Sowers; Kiana Matthews; Sara Mercader; Carole J Hickman; Richard T D'Aquila; Guorong Liu
Journal:  Commun Med (Lond)       Date:  2022-03-04

2.  Seroprevalence of Measles Antibodies in the Population of the Olomouc Region, Czech Republic-Comparison of the Results of Four Laboratories.

Authors:  Michal Krupka; Tereza Matusu; Helena Sutova; Katerina Wezdenkova; Renata Vecerova; Yvona Smesna; Milan Kolar; Hana Bilkova Frankova; Jana Krivankova; Miroslav Jorenek; Zdenek Novak; Milan Raska; Ondrej Holy
Journal:  Vaccines (Basel)       Date:  2022-01-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.